2020
Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival
Heller DR, Nicolson NG, Ahuja N, Khan S, Kunstman JW. Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival. JAMA Surgery 2020, 155: e195047. PMID: 31800002, PMCID: PMC6902102, DOI: 10.1001/jamasurg.2019.5047.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaNational Cancer DatabaseWhite patientsBlack patientsAdvanced diseaseOverall survivalClinical parametersDisease stageCancer DatabaseSurgical proceduresMultivariable Cox proportional hazards regression modelingTreatment inequitiesCox proportional hazards regression modelingPancreatic ductal adenocarcinoma (PDAC) survivalUnadjusted median overall survivalYounger ageProportional hazards regression modelingMedian overall survivalModest survival advantageStage II diseaseNew cancer diagnosesLess chemotherapyResectable cancerCohort studyPrimary outcome
2019
A phase 1 trial of the oral DNA methyltransferase inhibitor CC‐486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors
Gaillard SL, Zahurak M, Sharma A, Durham J, Reiss K, Sartorius‐Mergenthaler S, Downs M, Anders N, Ahuja N, Rudek M, Azad N. A phase 1 trial of the oral DNA methyltransferase inhibitor CC‐486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors. Cancer 2019, 125: 2837-2845. PMID: 31012962, PMCID: PMC6663621, DOI: 10.1002/cncr.32138.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAged, 80 and overAnorexiaAntineoplastic Combined Chemotherapy ProtocolsAzacitidineDepsipeptidesDNA Modification MethylasesDrug Administration ScheduleFemaleHistone Deacetylase InhibitorsHumansLong Interspersed Nucleotide ElementsMaleMaximum Tolerated DoseMethyltransferasesMiddle AgedNauseaNeoplasmsConceptsHistone deacetylase inhibitor romidepsinDisease control rateAdvanced solid tumorsPhase 1 studyCC-486Solid tumorsDose-escalation portionPhase 2 doseDose-limiting toxicityPossible clinical benefitPhase 1 trialDose-escalation designElement-1 methylationLINE-1 methylationStable diseaseCommon toxicitiesDose expansionExpansion cohortPrimary outcomeClinical benefitControl rateDrug exposureBlood samplesDay 1Dose levels
2017
High dose-rate Intra-Operative Radiation Therapy During High Risk Genitourinary Surgery: Initial Observations and a Proposal for its Study in Bladder Cancer
Kates M, Chappidi MR, Brant A, Milbar N, Sopko NA, Meyer C, Terezakis SA, Herman JM, Efron JE, Safar B, Tran PT, Ahuja N, Pierorazio PM, Bivalacqua TJ. High dose-rate Intra-Operative Radiation Therapy During High Risk Genitourinary Surgery: Initial Observations and a Proposal for its Study in Bladder Cancer. Bladder Cancer 2017, 3: 191-199. PMID: 28824947, PMCID: PMC5545919, DOI: 10.3233/blc-170104.Peer-Reviewed Original ResearchSurgical margin statusBladder cancerGenitourinary surgeryMargin statusInstitutional experienceIntra-operative radiation therapyRadiation therapyHigh-risk bladder cancerPositive surgical margin statusMulti-institutional registryRecurrence-free survivalEffective local controlGI complicationsSarcomatoid histologyAdvanced diseaseFree survivalComplication rateOverall survivalPrimary outcomeRetrospective reviewSuch patientsRecurrent tumorsUrothelial cancerWound infectionUrothelial histology
2015
Tracking Early Readmission After Pancreatectomy to Index and Nonindex Institutions: A More Accurate Assessment of Readmission
Tosoian JJ, Hicks CW, Cameron JL, Valero V, Eckhauser FE, Hirose K, Makary MA, Pawlik TM, Ahuja N, Weiss MJ, Wolfgang CL. Tracking Early Readmission After Pancreatectomy to Index and Nonindex Institutions: A More Accurate Assessment of Readmission. JAMA Surgery 2015, 150: 152-158. PMID: 25535811, PMCID: PMC4461067, DOI: 10.1001/jamasurg.2014.2346.Peer-Reviewed Original ResearchConceptsTertiary care referral centerPatient-level factorsNonindex hospitalEarly readmissionReferral centerMultivariable analysisPatterns of readmissionPostoperative drain placementRate of readmissionRisk of readmissionData of patientsAge 65 yearsHigh-volume institutionsDistal pancreatectomyPostoperative infectionPrimary outcomeLiver diseaseDrain placementInstitutional databaseRisk factorsPancreatectomyRetrospective analysisReadmissionMAIN OUTCOMEPatients